Press RELEASE
Lund – Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the company’s board of directors has appointed the company’s current CSO Helén and Held to the new president and CEO for Active Biotech AB Helén Held taking up the post on 1 July 2017 and will succeed Tomas Leanderson has been the company’s CEO since 2008.
Helén and Held has more than 20 years of experience on various positions in the pharmaceutical industry and has a broad experience within pharmaceutical development. Krebs has held various senior management positions in Active Biotech and has since 2011 been responsible for the company’s research and development.
– I am proud and happy that we Helén and Held have an internal candidate who can take over the role of CEO, ensuring continuity and an orderly handover. Helén has been instrumental in the changes that have been implemented in the company during the 2016/2017 and has a solid experience in the industry and I am convinced that she has the qualities required for designing the company’s strategy for the future and exploit the company’s opportunities, says chairman of the board, Mats Arnhög.
– I would also like to thank Tomas Leanderson, for his significant contributions to the company’s activities over a long period of time, he will also be available to the company during a transitional period, ” says Mats Arnhög.
– I am very happy and at the same time humbled by the confidence to lead Active Biotech on. I am well familiar with the company’s project and its potential and look forward to developing the portfolio further, and create value for the company, ” says Helén and Held.
Lund, 19 June 2017,
Active Biotech AB (publ)
For further information, please contact:
Mats Arnhög
Chairman of the board
Telephone: 08 54503770
Mobile: 0705 915096
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company focused on the development of drugs for the treatment of neurodegenerative/inflammatory diseases and cancer. Laquinimod, a substance in tablet form with unique immunomodulatory properties is in phase 2 trials for the treatment of primärprogressiv multiple sclerosis and Huntington’s disease. Anyara, a immunonkologisk substance, has undergone clinical phase 1-2/3 in patients with pancreatic, lung or renal cancer. Furthermore, the conducted commercial activities for the projects tasquinimod, paquinimod and SILC. For further information please visit www.activebiotech.com.
Active Biotech AB
(org.no. 556223-9227)
Box 724, 220 07 Lund, Sweden
Tel 046-19 20 00
This information is such information that Active Biotech AB is obligated to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government of, for publication
19 June 2017, there is a 15.30.
Helén and Held the new president and CEO for Active Biotech AB from 1 July 2017
